Use of a phosphopeptide able to block her3/p85 interaction for the treatment of her2 hyper-expressing tumours
OwnerRita Falcioni, Valentina Folgiero +2inventors
InventorsRita Falcioni, Valentina Folgiero, Selene Eleonora Di Carlo, Giulia Bon
Life of this patent
Estimating the term…
Abstract
The present invention concerns the use of a phosphopeptide able to block HER3/p85 interaction for the treatment of HER2 hyper-expressing tumours, such as, for example, metastatic mammary tumour, possibly in combination with other anti-tumour agents like, for example, trastuzumab
Claims20
A medicament comprising a phosphopeptide consisting of sequence:
- RDGGGPGGDpYAAMGACPA (SEQ ID NO:
- 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence.
A medicament comprising a phosphopeptide consisting of the following sequence:
- RDGGGPGGDpYAAMGACPA (SEQ ID NO:
- 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence, in an amount suitable for treatment of a tumour selected from the group consisting of a solid tumour, a primary or metastatic tumour, a HER2 and HER3 hyper-expressing and having elevated PI3K activity tumour or a primary or metastatic tumor, a tumour positive for BRAF oncogene expression, and a melanoma.
A pharmaceutical combination of a phosphopeptide consisting of sequence:
- RDGGGPGGDpYAAMGACPA (SEQ ID NO:
- 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence, with one or more anti-tumour active principles.
A pharmaceutical composition comprising a phosphopeptide consisting of sequence RDGGGPGGDpYAAMGACPA (SEQ ID NO:
- 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence alone or in combination with one or more anti-tumour active principles, as active principles, in combination with one or more pharmaceutically acceptable excipients and/or adjuvants.
A method to treat a medical condition of a patient, the method comprising
- administering to the patient an effective amount of a phosphopeptide consisting of sequence RDGGGPGGDpYAAMGACPA (SEQ ID NO:
- 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence
A method to treat a tumour in a patient the method comprising
- administering to the patient a phosphopeptide consisting of sequence RDGGGPGGDpYAAMGACPA (SEQ ID NO:
- 1), or a nucleotide sequence encoding for said phosphopeptide or a vector comprising said nucleotide sequence, in an effective amount to treat a tumour selected from the group consisting of a solid tumour, a primary or metastatic tumour, a HER2 and HER3 hyper-expressing and having elevated PI3K activity tumour or a primary or metastatic tumor, a tumour positive for BRAF oncogene expression, and a melanomas.
Dependencies are inferred from the claim text.